[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334500-105":59,"doc-detail-334500-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","molecular-crosstalk-between-muc1-and-stat3-influences-the-anti-proliferative-effect-of-napabucasin-in-epithelial-cancers-research-summary","Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers - Research summary","","MUC1 is a transmembrane glycoprotein overexpressed and aberrantly glycosylated in epithelial cancers, while STAT3 is aberrantly activated and controls transcriptional programs for proliferation, survival, angiogenesis, and differentiation. The study examines evidence for an auto-inductive loop in which STAT3 and MUC1 regulate each other’s expression, promoting EMT and drug resistance. Napabucasin, a discontinued STAT3 inhibitor, shows increased efficacy in cancers with higher MUC1 expression, suggesting a precision-medicine stratification for epithelial cancer therapy.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-crosstalk-between-muc1-and-stat3-influences-the-anti-proliferative-effect-of-napabucasin-in-epithelial-cancers-research-summary/334500/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-crosstalk-between-muc1-and-stat3-influences-the-anti-proliferative-effect-of-napabucasin-in-epithelial-cancers-research-summary/334500.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"What determines whether tumor cells are more sensitive to Napabucasin treatment?","Question",{"text":112,"@type":113},"Higher MUC1 expression increases the sensitivity of cancer cells to Napabucasin. This suggests high-MUC1 tumors may have better therapeutic outcomes.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},334500,1790072571,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":41,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMolecular crosstalk between MUC1 and STAT3 influences the anti‑proliferative effect of Napabucasin in epithelial  \ncancers  \nMukulika Bose1*, Alexa Sanders2, Aashna Handa1, Aabha Vora1, Manuel R. Cardona1, Cory Brouwer2 & Pinku Mukherjee1*  \nMUC1 is a transmembrane glycoprotein that is overexpressed and aberrantly glycosylated in epithelial cancers. The cytoplasmic tail of MUC1 (MUC1 CT) aids in tumorigenesis by upregulating the expression of multiple oncogenes. Signal transducer and activator of transcription 3 (STAT3) plays a crucial role in several cellular processes and is aberrantly activated in many cancers. In this study, we focus on recent evidence suggesting that STAT3 and MUC1 regulate each other’s expression in cancer cells inan auto‑inductive loop and found that their interaction plays a prominent role in mediating epithelial‑ to‑mesenchymal transition (EMT) and drug resistance. The STAT3 inhibitor Napabucasin was in clinical trials but was discontinued due to futility. We found that higher expression of MUC1 increased the sensitivity of cancer cells to Napabucasin. Therefore, high‑MUC1 tumors may have a better outcome to Napabucasin therapy. We report how MUC1 regulates STAT3 activity and provide a new perspective on repurposing the STAT3‑inhibitor Napabucasin to improve clinical outcome of epithelial cancer treatment.  \nKeywords MUC1, STAT3, Napabucasin, Gastrointestinal cancers, Precision medicine  \nSTAT3 belongs to a family of transcription factors comprising STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. In humans, this is encoded by the STAT3 gene. STAT3 is activated by several cytokines and growth factors such as IL-6, IL-9, IL-10, IL-27, TNF-α, MCP-1, EGF, PDGF, G-CSF, and GM-CSF. Active STAT3 plays an important role in tumorigenesis by regulating transcription of genes associated with cell development, differentiation, proliferation, survival, and angiogenesis1. STAT3 activation is detected in several malignancies, and its inhibition led to reversal of the malignant phenotype.  \nSTAT3 activation has been described in nearly 70% of solid and hematological tumors1. STAT3 is constitutively activated by phosphorylation of Tyr705, in primary human pancreatic ductal adenocarcinomas (PDA), in PDA cell lines, and in PDA xenografts2. Studies in STAT3 conditional knockout mice demonstrate that the STAT3 pathway is inactive in normal pancreas, and it is not required for pancreatic development and homeostasis2. However, STAT3 was found to be necessary for the development of the acinar-to-ductal metaplasia process, an early event in PDA pathogenesis, which is mediated by ectopic expression of the Pdx1 transcription factor, a key regulator in early pancreatic cancer development3. Functional inactivation of STAT3 in a subset of PDA cell lines led to significant inhibition in cell proliferation in vitro and reduced tumor growth in vivo. Inhibition of activated STAT3 resulted in the delay of G1/S-phase progression due to inhibition of cyclin-dependent kinase 2 activity because of increased expression of p21/WAF1. Overall, the study clearly showed that with malignant transformation, activated STAT3 promotes proliferation of cells by modulating G1/S-phase progression and supports the malignant phenotype of human PDA cells4.  \nInterestingly, activation of STAT3 also suppresses tumor growth5 and induces differentiation and apoptosis in some contexts6,7. The mechanisms underlying STAT3’s diverse and sometimes opposing roles are still largely unknown. It is assumed that STAT3 recruits specific co-activators and activates distinct gene expression  \n1Department of Biological Sciences, UNC Charlotte, Charlotte, NC 28223, USA. 2Department of Bioinformatics, UNC Charlotte, Charlotte, NC 28223, USA.*[email: mbose@uncc.edu](email: mbose@uncc.edu); [pmukherj@uncc.edu](pmukherj@uncc.edu)  \n[www. nature.com/scientificreports/](www. nature.com/scientifi","cbCaijk37haQ019K","https://ap.wps.com/l/cbCaijk37haQ019K","pdf",4020295,12,"English","# Background: MUC1 and STAT3 in epithelial cancers\n## STAT3 activation and oncogenic transcriptional roles\n## STAT3 functions and context-dependent effects\n# STAT3-MUC1 signaling and auto-inductive regulation\n## MUC1 as a downstream target of STAT3\n## Direct binding to JAK1/STAT3 and feedback activation\n# Therapeutic implications for Napabucasin\n## Clinical trial outcome and study rationale\n## Higher MUC1 predicts sensitivity to Napabucasin","[{\"question\":\"What determines whether tumor cells are more sensitive to Napabucasin treatment?\",\"answer\":\"Higher MUC1 expression increases the sensitivity of cancer cells to Napabucasin. This suggests high-MUC1 tumors may have better therapeutic outcomes.\"}]","Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers - Research summary | PDF",1790006927]